Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk

Abstract

Treatment with FCM is associated with a high risk of developing severe and prolonged hypophosphatemia and should therefore be monitored. Hypophosphatemia risk appears to be substantially lower with IIM.